Company Monitoring Page for CRISPR-Therapeutics

latest headlines for company on cafepharma

Vertex puts a blockbuster valuation on its CRISPR deal
EP Vantage
Tue, 04/20/21 - 11:05 am
Tags:
Vertex Pharmaceuticals, CRISPR Therapeutics, CRISPR, gene editing, CTX001, M&A
3 Biotech Stocks That Could Explode Higher in 2021
Motley Fool
Mon, 12/21/20 - 10:58 am
Tags:
biotech, biotech stocks, clinical trials, FDA, Argenx, Axsome Therapeutics, CRISPR Therapeutics
Where Will CRISPR Therapeutics Be in 10 Years?
Motley Fool
Tue, 12/15/20 - 10:44 am
Tags:
CRISPR, CRISPR Therapeutics
Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting
Yahoo/Bloomberg
Fri, 12/4/20 - 11:09 am
Tags:
ASH2020, Trillium Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Vertex Pharmaceuticals
CRISPR and Vertex Release Additional Data for Blood Disease Treatment
Motley Fool
Wed, 11/4/20 - 10:50 pm
Tags:
CRISPR Therapeutics, CRISPR, Vertex Pharmaceuticals, CTX001, beta thalassemia, sickle cell disease
Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode
Motley Fool
Mon, 11/2/20 - 10:20 am
Tags:
CRISPR, CRISPR Therapeutics, clinical trials
CRISPR stock slides as CAR-T death overshadows signs of efficacy
Fierce Biotech
Wed, 10/21/20 - 10:54 am
Tags:
CRISPR, CRISPR Therapeutics, CAR-T, patient deaths
Where Will CRISPR Therapeutics Be in 5 Years?
Motley Fool
Fri, 07/17/20 - 10:53 am
Tags:
CRISPR Therapeutics
Biopharma Companies Continue to Expand, Add Jobs Despite Ongoing Pandemic
BioSpace
Tue, 06/30/20 - 11:44 pm
Tags:
pharma industry, biotech, pandemic, COVID-19, hirings, AGC Biologics, Grail, Grifols, CRISPR Therapeutics, Sana Biotechnology, Point, Sanofi, Medpharm, Regeneron
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment
Fierce Biotech
Mon, 06/15/20 - 10:35 am
Tags:
Vertex Pharmaceuticals, CRISPR Therapeutics, CTX001, gene editing, sickle cell disease, beta thalassemia
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
BioPharma Dive
Fri, 06/12/20 - 11:11 am
Tags:
CRISPR, gene therapy, beta thalassemia, sickle cell disease, CRISPR Therapeutics, Vertex, Bluebird Bio, EHA
Derailed by the pandemic, FDA offers CRISPR, Vertex drug program VIP status for its comeback play
Endpoints
Mon, 05/11/20 - 10:16 am
Tags:
CRISPR Therapeutics, Vertex Pharmaceuticals, CTX001, pandemic, COVID-19
CRISPR Therapeutics braces for 'severe impact' from COVID-19 crisis
Fierce Biotech
Wed, 04/1/20 - 09:54 am
Tags:
CRISPR, CRISPR Therapeutics, COVID-19, clinical trials
Here's Why CRISPR Stocks Fell in January
Motley Fool
Wed, 02/5/20 - 10:07 am
Tags:
Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, CRISPR
3 Biotech Start-Ups That Could Soar in 2020
Motley Fool
Mon, 01/27/20 - 10:50 am
Tags:
Cue Biopharma, Rubius Therapeutics, CRISPR Therapeutics
More CRISPR Stock Catalysts Ahead
Motley Fool
Mon, 11/25/19 - 09:38 am
Tags:
gene editing, CRISPR, Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Investors Business Daily
Wed, 11/20/19 - 09:53 am
Tags:
CRISPR Therapeutics, gene editing, CRISPR, beta thalassemia, sickle cell disease
That $335M JV Bayer set up on CRISPR/Cas9? They’re letting the biotech partner carry on
Endpoints
Mon, 10/21/19 - 04:34 pm
Tags:
Bayer, CRISPR Therapeutics, CRISPR-Cas9
Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
Motley Fool
Sun, 06/9/19 - 01:41 pm
Tags:
gene editing, gene therapy, DMD, Duchenne Muscular Dystrophy, Vertex Pharmaceuticals, CRISPR Therapeutics, Exonics
Vertex sets sights on DMD gene therapy, joining crowded field
Biopharma Dive
Fri, 06/7/19 - 10:17 am
Tags:
Vertex Pharmaceuticals, DMD, M&A, CRISPR Therapeutics, Exonics, gene therapy

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.